Francis O'Neill, MD
Interventional Cardiology · East Meadow, NYNPI 1538521604
Payments from drug & device makers
What this record shows
This record is dominated by grants: $14,300 of the $16,541 with a category attached, or 86.4%. 17 manufacturers reported payments, led by Medtronic at 48.7% of the total. Reporting peaked in 2022 at $15,389 and has fallen 98.6% since, to $214 in 2025.
Across 66 payments — averaging $250.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$313
- Johnson & Johnson$252
- Amgen$241
- Abiomed$237
- plus $387 from 11 others
What the payments were for
- Grants$14,30086%
- Food & beverage$2,07313%
- Education$1541%
- Entertainment$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $8,053 |
| Abbott | 11 | $7,059 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $313 |
| Johnson & Johnson | 8 | $252 |
| Amgen | 8 | $241 |
| Abiomed | 3 | $237 |
| Astellas Pharma US Inc | 1 | $88 |
| Pfizer | 4 | $82 |
| Lantheus Medical Imaging, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Edwards Lifesciences | 1 | $28 |
| Cardiovascular Systems Inc. | 2 | $25 |
| Boston Scientific | 1 | $25 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Merck | 1 | $17 |
| Opsens Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$8,000
- CARDIOMEMS$164
- MitraClip$149
- Impella$130
- XARELTO$125
- GALLANT$120
- Repatha$109
How this compares
$16,541 in reported general payments places this provider in the 60th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 34 | $249 |
| Metoprolol Succinate | 13 | $116 |
| ClopidogrelClopidogrel Bisulfate | 14 | $76 |
| Carvedilol | 11 | $71 |
| Furosemide | 19 | $62 |
| Metoprolol Tartrate | 18 | $43 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in East Meadow
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.